Back to Search
STEVEN HERSCH, M.D, PH.D.
M.D, PH.D.
Neurology Physician
NPI: 1932184173Individual
Specialties, Licenses & Credentials
Neurology PhysicianPrimary
Psychiatry & Neurology — Neurology
Code: 2084N0400X
210200(MA)
Research & Publications (20)
Translating therapies for Huntington's disease from genetic animal models to clinical trials.
PMID 15717031·NeuroRx·2004
6-review
Neuroprotection for Huntington's disease: ready, set, slow.
PMID 18394565·Neurotherapeutics·2008
6-review
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.
PMID 16434666·Neurology·2006
2-rct
Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation.
PMID 12869810·Curr Opin Neurol·2003
6-review
Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease.
PMID 19664996·Anal Biochem·2009
7-preclinical
Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications.
PMID 18712713·Am J Med Genet B Neuropsychiatr Genet·2009
8-other
Linking SNPs to CAG repeat length in Huntington's disease patients.
PMID 18931668·Nat Methods·2008
8-other
Metabolite identification using a nanoelectrospray LC-EC-array-MS integrated system.
PMID 18576668·Anal Chem·2008
8-other
Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?
PMID 19076442·Ann N Y Acad Sci·2008
6-review
Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.
PMID 18337273·Brain·2008
8-other
Mechanisms of copper ion mediated Huntington's disease progression.
PMID 17396163·PLoS One·2007
7-preclinical
Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models.
PMID 17409194·Hum Mol Genet·2007
7-preclinical
A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
PMID 17925440·Proc Natl Acad Sci U S A·2007
7-preclinical
Drug targeting of dysregulated transcription in Huntington's disease.
PMID 17379386·Prog Neurobiol·2007
6-review
Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice.
PMID 18032664·J Neurosci·2007
4-observational
Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cells.
PMID 16873024·Chem Biol·2006
8-other
Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective.
PMID 16595660·J Biol Chem·2006
7-preclinical
Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures.
PMID 16755582·Mov Disord·2006
8-other
Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study.
PMID 16914060·BMC Med Genet·2006
8-other
Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.
PMID 16127709·J Comp Neurol·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- MASS GENERAL HOSPITAL, WACC, SUITE 835
BOSTON, MA 02114 - Phone
- (617) 726-1254
Quick Facts
- NPI
- 1932184173
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile